Aicardi-Goutieres Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

This reports provides a data-driven overview of the current and future competitive landscape in Aicardi-Goutieres Syndrome therapeutics.

Synopsis

• There will be more than 4,000 prevalent cases of AGS each in 2022 across the 16 countries covered in the publisher's epidemiology forecast.
• No FDA-approved marketed drugs are available for AGS, only symptomatic treatment is indicated for disease management.
• The drug currently in late-stage clinical development targets tyrosine kinase.
• Non-commercial sponsors dominate clinical trial development in AGS.
• No deals involving companies developing AGS assets were seen over the past 10 years.
• No regulator filing or commercial launch is expected for AGS in the next 18 months.

Scope

The publisher's Aicardi-Goutieres Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2022 Update combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Late-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Sponsors and Geography
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Aicardi-Goutieres Syndrome market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Aicardi-Goutieres Syndrome market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.